Neurology News

Neurocrine Biosciences Inc. recently presented data on comorbidities, polypharmacy and treatment patterns of patients prescribed benztropine who also were being treated with antipsychotic medications.

The FDA has accepted a new drug application for zilucoplan, an investigational treatment for generalized myasthenia gravis in adults who are acetylcholine receptor antibody positive, UCB announced in a released statement.

Gantenerumab, a treatment for mild cognitive impairment due to Alzheimer’s disease, did not meet the primary endpoint of slowing cognitive decline in a phase 3 clinical trial, Genentech announced in a released statement.

The FDA has accepted a new drug application from Amneal Pharmaceuticals Inc. for IPX203, an oral formulation of carbidopa/levodopa extended-release capsules for treatment of Parkinson’s disease, the company announced in a press release.

Oral ENT-01 treatment was safe and associated with improvements in constipation among patients with Parkinson’s disease, a study in Annals of Internal Medicine found.

Viz.ai has announced that 85% of aneurysms detected by Viz Aneurysm, its artificial intelligence-based detection tool, previously had not been referred for neurovascular review.

For adults in the U.K., preexisting neuropsychiatric conditions and having a prescription for a related treatment carried a significantly increased risk of severe outcomes from COVID-19 and other severe acute respiratory infections.

SARS-CoV-2-related neurologic effects endured among children and adolescents in the United States who were hospitalized in 2021 for COVID-19 or multisystem inflammatory syndrome, researchers reported in JAMA Neurology.

Cerveau Technologies Inc. has announced a license agreement with Lexeo Therapeutics Inc. that will allow Lexeo to use an investigational imaging agent from Cerveau for the assessment of neurofibrillary tangles in the brain.

In this edition, we bring you more news and Healio-exclusive interviews from the American Neurological Association Annual Meeting.